Plain-English translation of NCT06708897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called ZE50-0134 to see if it can help people whose blood cancers (chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas) have stopped responding to other treatments. The study has two parts: first, researchers will find the right dose by gradually increasing it in small groups of patients; then, they will test that dose in a larger group to understand how well and safely the medication works.
People with blood cancers that no longer respond to standard treatments like venetoclax or BTK inhibitors have very limited options. This medication is being tested because it may offer a new way to fight these cancers when other therapies have failed.
You likely qualify if…
You likely don't qualify if…
You will receive the study medication at gradually increasing doses (Part 1) or at a specific dose determined to be safe and effective (Part 2). You will have regular clinic visits for blood tests, physical exams, and scans to monitor how you respond to the treatment and check for any side effects. The trial will involve ongoing visits and monitoring over several months as researchers track your cancer response and your overall health.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States